<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BD1E610A-D3A8-488F-9DEE-2BE1326B18E9"><gtr:id>BD1E610A-D3A8-488F-9DEE-2BE1326B18E9</gtr:id><gtr:name>Second Military Medical University</gtr:name><gtr:address><gtr:line1>Epidemiology</gtr:line1><gtr:line2>Second Military Medical University</gtr:line2><gtr:line3>800 Xiangyin Road</gtr:line3><gtr:postCode>200433</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BD1E610A-D3A8-488F-9DEE-2BE1326B18E9"><gtr:id>BD1E610A-D3A8-488F-9DEE-2BE1326B18E9</gtr:id><gtr:name>Second Military Medical University</gtr:name><gtr:address><gtr:line1>Epidemiology</gtr:line1><gtr:line2>Second Military Medical University</gtr:line2><gtr:line3>800 Xiangyin Road</gtr:line3><gtr:postCode>200433</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/62B87FD7-4D4A-410E-BCE5-35A024BE8D61"><gtr:id>62B87FD7-4D4A-410E-BCE5-35A024BE8D61</gtr:id><gtr:firstName>Yong-Jie</gtr:firstName><gtr:surname>Lu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701163"><gtr:id>CFAA39FA-DA2B-4811-8C60-2E1A3AB1B9E1</gtr:id><gtr:title>Identification of the recurrent chromosome breakpoints and associated genes in prostate cancer using a novel approach</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701163</gtr:grantReference><gtr:abstractText>We aim to identify the critical genetic defects in prostate cancer and evaluate their clinical potential. Prostate cancer is the most common tumour in Western men.
Chromosomes are the carriers of genetic information in the cell. They are damaged during cancer development. Abnormal chromosomes by the re-joining of damaged chromosome fragments can switch genes on or off abnormally; which play a key role in cancer development. The role of these abnormal chromosomes in prostate cancer is largely unknown. 
With recent advances in genetic technology, new approaches can be used to detect these genetic defects more efficiently. In this project we are planning to identify systematically the abnormal chromosomes in prostate cancer using a novel approach. The whole genome will be tested to detect these chromosome changes. Genes associated with these abnormal chromosomes will be identified and their clinical significance such as the ability to predict tumour progression will be evaluated in a large series of tumour samples. 
We hope that we can use the information obtained to predict patient outcome and develop novel forms of treatment.</gtr:abstractText><gtr:technicalSummary>Chromosome rearrangement is the hallmark of human haematological and soft tissue malignancies. However, its significance has not been well investigated in prostate cancer, the most common malignancy in Western men. The recent identification of the fusion of ETS family genes to TMPRSS2 and other genes highlighted the importance of chromosome rearrangement in prostate tumourigenesis. We have a long-established interest in chromosome rearrangement and have identified a frequent chromosome translocation, t(4:6). We recently applied high-density SNP arrays to identify precisely chromosome alterations and have developed a high-resolution karyotyping approach to facilitate the identification of genes affected by chromosome rearrangement. Here, as a further extension of the microarray technology, I plan to identify, using a novel approach, the recurrent chromosome breakpoints in prostate cancer and clarify the nature of the genomic sequence and the effect on genes located around the breakpoints. This approach, combining SNP array analysis for chromosome breakpoint identification and molecular copy-number counting for breakpoint cloning, enables for the first time systematic and rapid identification and clarification of chromosome breakpoints in cancer. This project will be carried out in 3 steps. 1. 500K SNP array analysis for genome-wide detection of recurrent chromosome breakpoints in prostate cancer. 2. Identification of the breakpoint DNA sequences and the fusion partners and determination of the effect on associated genes. 3. Evaluation of the clinical significance of the fusion events in a large series of clinical samples. All techniques have been established and tumour samples collected. We predict that this study will reveal fully the role of chromosome rearrangements and their associated genes in prostate cancer development and progression. The ultimate goal is to identify genetic alterations as cancer progression markers and therapeutic targets.</gtr:technicalSummary><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>300292</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and the London Genome Centre</gtr:department><gtr:description>Exon sequencing -Genome Centre</gtr:description><gtr:id>5D45D944-A263-43A5-AFA6-D127252930FC</gtr:id><gtr:impact>The samples are currently being processed and the results not yet known.</gtr:impact><gtr:outcomeId>UQZyq1sG8fA-1</gtr:outcomeId><gtr:partnerContribution>The Genome Centre is providing access to both the Fluidigm AcessArray and the Illumina MiSeq platforms on which we will perform exon sequencing of target genes. Further more, the Genome Centre is providing their technical expertise to run the samples for us.</gtr:partnerContribution><gtr:piContribution>We have provided 48 clinical prostate cancer samples (in the first instance) to the Genome Centre for exon amplication and sequencing of target genes identified from the previous MRC funded project (G0701163).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prostate cancer international cancer genome consortium</gtr:description><gtr:id>7497AE2A-138F-47F3-9E50-7FBC8F7F8FF5</gtr:id><gtr:impact>Genomic sequencing is ongoing. No outcome yet.</gtr:impact><gtr:outcomeId>P8GP4MmYg3i-1</gtr:outcomeId><gtr:partnerContribution>My Chinese prostate cancer samples (DNA from 25 cases with cancer and germline controls) will be sequenced for the entire genome with cost coverred by the ICGC programme funding.</gtr:partnerContribution><gtr:piContribution>Contribute genomic DNA from 25 prostate cancer cases (with cancer and germline controls) to be sequenced for the entire genome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Secondary Military Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Chinese prostate cancer genetic study group</gtr:description><gtr:id>A232CD2A-1638-4EDE-BEA7-0626F9FA9EF4</gtr:id><gtr:impact>PubMed ID: 19767753</gtr:impact><gtr:outcomeId>68BFD040FD2-1</gtr:outcomeId><gtr:partnerContribution>Contributed clinical samples and data analysis as well as pathological and epidemiological expertise.</gtr:partnerContribution><gtr:piContribution>Based on our genetic research, the PI (Dr. Yong-Jie Lu) established this colaboration group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PRACTICAL prostate cancer consortium</gtr:description><gtr:id>6BC46D25-91FB-4E10-8F87-8DDCD1640457</gtr:id><gtr:impact>19767753</gtr:impact><gtr:outcomeId>17A1AF55231-1</gtr:outcomeId><gtr:partnerContribution>Provided prostate cancer specific gene data relevant to our study.</gtr:partnerContribution><gtr:piContribution>Contributed genetic data from Chinese prostate cancer samples through our Chinese colaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presenting overview of work for prospective funder</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>80495491-2093-46E6-8174-512063612EB8</gtr:id><gtr:impact>Prof. Rickman (Prof of Philosophy) attended the talk. His interest in the study prompted questions and discussions.

Provided funding support for our future research work (&amp;pound;18,000 for a Dry Store liquid nitrogen tank).</gtr:impact><gtr:outcomeId>oFb9HXbTiD9</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DE07669-5CB0-4C19-A409-F433F27F3884</gtr:id><gtr:impact>A press statement was released about our study showing that androgen induces a common genetic change in prostate cancer. This was broadcasted by BBC TV news, dozens of national and international newspapers and online news media.

Enquiries from people regarding prostate cancer prevention.</gtr:impact><gtr:outcomeId>ZQftL5qg5Sa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.telegraph.co.uk/health/healthnews/8132665/Genes-that-mutate-in-prostate-cancer-identified.html and many others</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations at scientific meetings including AACR annual meeting 2010, EU solid tumour genetics meeting (2009 and 2011) and Prostate cancer blue sky meeting 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7AD0642D-4FFE-4175-B220-92C8A9882058</gtr:id><gtr:impact>Release of scientific discovery into the the research community so that people can using this info when design their relevant studies.</gtr:impact><gtr:outcomeId>56cddad3c87d71.43372382</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Attending Orchid Charity Christmas Reception</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E6856CF0-4C9F-4829-8397-C676817F1B55</gtr:id><gtr:impact>At the Orchid Charity Christmas Reception, the PI described our relevant research results and its implication to the charity office staff, donors and fund raisers to promote cancer awareness.

The audience were very interested in our findings and very supportative of our future work to identify the risk factor(s) in UK men or protective factor(s) in Chinese, which lead to the different incidence of prostate cancer. Some audience asked for advice in life style to prevent prostate cancer.</gtr:impact><gtr:outcomeId>87F2A9AED2D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Orchid 'low-down' magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2BB0A62B-763A-4311-9576-258DF0D4E845</gtr:id><gtr:impact>The PI was interviewed and an article was written for the Orchid low-down magazine, which highlights research developments, fundraising and lifestyle information sorrounding prostate cancer. In the 2009 article, the PI gave information about past and present research work aimed at the general public. In the 2010 article, the PI gave general information about his life and research work. In the 2011 article, the PI gave information about the ongoing prostate cancer research with Chinese collaborators and information about one of his business trips to China.

A high school girl was interested in our research work and took a work placement in the laboratory during the Xmas school holiday period.</gtr:impact><gtr:outcomeId>CA21C636F58</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement at charity event (CRUK - Half Marathon)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>07FBB104-45EA-4212-8FC3-A88414A7CC44</gtr:id><gtr:impact>Volunteers were required by CRUK to demonstrate extracting DNA from strawberries to the general public at the Royal Parks Half Marathon. The aim of this was to encourage members of the public to engage in science and learn about the kind of work that research scientists are involved in with a view to fundraising.

By talking to members of the public about my reserach, those individuals are better informed about cancer research and about the impact that their donations can have.</gtr:impact><gtr:outcomeId>jAgZX616q2s</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel bursary to attend scientific meeting (Young Prostate Researchers symposium committee)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Young Prostate Researchers</gtr:fundingOrg><gtr:id>72B31440-E840-4621-B884-8739DA2E3EEE</gtr:id><gtr:outcomeId>cSSKew7J2RR0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172850</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The genomic changes in prostate cancer development and their therapeutic potential (Orchid 2012-2013)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Orchid</gtr:fundingOrg><gtr:id>7FCC910B-E761-4C8A-B7B9-3DE2ADC53E75</gtr:id><gtr:outcomeId>RLh5UfKCKs80</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>171680</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The genomic changes in prostate cancer development and their therapeutic potential (Orchid 2011-2012)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Orchid</gtr:fundingOrg><gtr:id>2626EA54-2A08-4B7F-88E1-76BC10F651B7</gtr:id><gtr:outcomeId>AMkPUYhkqpc0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>165000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The genomic changes in prostate cancer and their therapeutic potential (Orchid 2010-2011)</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Orchid</gtr:fundingOrg><gtr:id>8B022380-80F6-4CDE-8BF9-E70DF35649F0</gtr:id><gtr:outcomeId>B9BEE2AB1160</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel bursary to atttend scientific meeting (NCRI annual meeting)</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>National Cancer Research Institute (NCRI)</gtr:fundingOrg><gtr:id>CF895EC7-28B6-400A-8744-97B81AA56F22</gtr:id><gtr:outcomeId>c6QowWUSi4b0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genetic alterations in prostate cancer: the risk factors, mechanism and opportunity for cancer therapy and prevention (Orchid funding 2013-2014)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Orchid</gtr:fundingOrg><gtr:id>E26C7B05-DCA4-4F5A-BB4B-E544FFF1695C</gtr:id><gtr:outcomeId>Kg3C3CLxuBo</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel bursary to attend scientific meeting (AICR)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>C6421D15-8789-4D7E-A9E3-E42A130CC276</gtr:id><gtr:outcomeId>sKU5DDJyegn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59140</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confirmation of TCBA1(NKAIN2) as a candidate tumour suppressor gene at 6q region in prostate cancer (Prostate Action)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>9044E005-899E-4E49-B413-C01CA3AA6F18</gtr:id><gtr:outcomeId>q1PbxcMbjsn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have analysed 39 UK and 31 Chinese prostate cancer samples by Afimatrix array 6.0 and generated large genomic alteration data. We established the prostate cancer genomic alteration SNP microarray database at our institute and submissed the dataset to Gene Expression Olimbus for the use of other researchers</gtr:description><gtr:id>36180389-CC92-4FE3-AA3A-6CB8EFB12E45</gtr:id><gtr:impact>Other research used the data for genetic alterations that they interested in.
Used by the CRUK funded prostate cancer international cancer genome consortium (ICGC) study to interpret the genomic changes together with the genome sequencing data.</gtr:impact><gtr:outcomeId>56cddf3654ea68.00829364</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prostate cancer genomic alteration SNP microarray database at our institute and dataset at Gene Expression Olimbus</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>TMPRSS2:ERG was found in about half of prostate cancers in the Western countires but we found that it was rarely present in the Chinese ones. We hypothesised that the differences in androgen level and androgen receptor activity between these populations would contribute to this genetic difference. Consequently, we found that androgen induces TMPRSS2:ERG fusion in non-malignant prostate epithilial cells by stimulating gene proximity and reducing PWIL1 expression.</gtr:description><gtr:id>A3D75038-E815-441E-BABB-B76DFBA6D0DC</gtr:id><gtr:impact>Collaborations to further explore the mechanism in prostate carcinogenesis and cancer prevention has been discussed and established.</gtr:impact><gtr:outcomeId>gJrsBnKHEqL</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Androgen induce TMPRSS2:ERG fusion in non-malignant prostate epithilial cells</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D5A1DC55-F09D-4C83-A289-A2807276BB71</gtr:id><gtr:title>Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89e234008e0fee074a9c887639935140"><gtr:id>89e234008e0fee074a9c887639935140</gtr:id><gtr:otherNames>Bastus NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>EXNRzdLL77P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86AAD992-A67E-4AF7-B5F2-E31AAEDF28B4</gtr:id><gtr:title>Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer.</gtr:title><gtr:parentPublicationTitle>American journal of cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d9642c171db24c59670da5336008253"><gtr:id>9d9642c171db24c59670da5336008253</gtr:id><gtr:otherNames>Mao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2156-6976</gtr:issn><gtr:outcomeId>pm_12879_29_21994901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13BBFB2E-8FAC-4E5F-82C0-BC37F84FFD23</gtr:id><gtr:title>Use of SNPs in cancer predisposition analysis, diagnosis and prognosis: tools and prospects.</gtr:title><gtr:parentPublicationTitle>Expert opinion on medical diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039d0f7a618010fb33182e7ee85aeb1d"><gtr:id>039d0f7a618010fb33182e7ee85aeb1d</gtr:id><gtr:otherNames>Boyd LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1753-0059</gtr:issn><gtr:outcomeId>1DE466A4EDB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8392CD6-2686-4E44-81D4-61FA5F140881</gtr:id><gtr:title>The complexity of prostate cancer: genomic alterations and heterogeneity.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039d0f7a618010fb33182e7ee85aeb1d"><gtr:id>039d0f7a618010fb33182e7ee85aeb1d</gtr:id><gtr:otherNames>Boyd LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>pm_12879_29_23132303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94EAB3BF-8EEB-4DFE-A51C-2680900B3080</gtr:id><gtr:title>NKAIN2 functions as a novel tumor suppressor in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d9642c171db24c59670da5336008253"><gtr:id>9d9642c171db24c59670da5336008253</gtr:id><gtr:otherNames>Mao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58b5b6f93e21e4.17695500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02D363FE-2C9D-42C3-ADB7-0CFC4E836490</gtr:id><gtr:title>High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039d0f7a618010fb33182e7ee85aeb1d"><gtr:id>039d0f7a618010fb33182e7ee85aeb1d</gtr:id><gtr:otherNames>Boyd LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>pm_12879_29_22334418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C924188C-6EF4-4B61-B7C2-DE7A8C7A7D6F</gtr:id><gtr:title>Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d9642c171db24c59670da5336008253"><gtr:id>9d9642c171db24c59670da5336008253</gtr:id><gtr:otherNames>Mao X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>Gwq96fTsWLi</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701163</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>